An Open Study of Adjunct OROS-Methylphenidate in Children Who Are Atomoxetine Partial Responders: II. Tolerability and Pharmacokinetics
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: The aim of this study was to evaluate the tolerability of adding OROS methylphenidate (MPH) to children who are partial responders to atomoxetine (ATMX) in the treatment of attention-deficit/hyperactivity disorder (ADHD). METHODS: This was a two-phase, 7-week, open study in children aged 6-17 years. Phase 1 initiated ATMX for a minimum of 4 weeks. Phase 2 entered partial responders to ATMX and added OROS MPH to their regimen. Safety was assessed using blood pressure and heart rate measurements, electrocardiogram readings, AEs, laboratories, and ATMX levels. RESULTS: Fifty subjects who were partial responders to ATMX received the combination therapy, with 41 subjects completing the entire protocol. As reported elsewhere (Wilens et al., 2009 ), OROS MPH added to partial responders of ATMX was accompanied by a 40% reduction in the ADHD rating scale score and improvements in executive functioning. However, the combination of ATMX plus OROS MPH was associated with greater rates of insomnia, irritability, and loss of appetite compared to ATMX alone. A small significant increase in diastolic blood pressure was observed during adjunctive OROS MPH, with no clinically meaningful changes in electrocardiogram (ECG) parameters during the study. ATMX levels and liver function tests did not significantly change during the combination treatment. CONCLUSION: Adjunct OROS MPH in ATMX partial responders yielded an additive adverse effect burden in this short-term study. Further controlled research with larger samples of children is warranted.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pliszka, S. (2007) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/chi.0b013e318054e724 · Cited by 1,765
Michelson, D., Faries, D., Wernicke, J., Kelsey, D., Kendrick, K., Sallee, F. R., Spencer, T., & the Atomoxetine ADHD Study Group (2001) · Pediatrics · doi:10.1542/peds.108.5.e83 · Cited by 666
Wolraich, M. L., Greenhill, L. L., Pelham, W., Swanson, J., Wilens, T., Palumbo, D., Atkins, M., McBurnett, K., Bukstein, O., August, G., et al. (2001) · Pediatrics · doi:10.1542/peds.108.4.883 · Cited by 502
Self-citationNewcorn, J. H., Kratochvil, C. J., Allen, A. J., Casat, C. D., Ruff, D. D., Moore, R. J., Michelson, D., & Atomoxetine/Methylphenidate Comparative Study Group (2008) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2007.05091676 · Cited by 336 · cited 3×
“%) during combination treatment in this study is approximately twice the rates of these common AEs typically reported in shortterm studies of OROS MPH monotherapy (Wolraich et al. 2001; Stein et al. 2003; Wilens et al. 2006b; Newcorn et al. 2008).”
Swanson, J. M., Wigal, S. B., Wigal, T., Sonuga-Barke, E., Greenhill, L. L., Biederman, J., Kollins, S., Nguyen, A. S., DeCory, H. H., Hirshe Dirksen, S. J., et al. (2004) · Pediatrics · doi:10.1542/peds.113.3.e206 · Cited by 238
Self-citationCardiovascular Effects of Atomoxetine in Children, Adolescents, and Adults
Wernicke, J. F., Faries, D., Girod, D., Brown, J. W., Gao, H., Kelsey, D., Quintana, H., Lipetz, R., Michelson, D., & Heiligenstein, J. (2003) · Drug Safety · doi:10.2165/00002018-200326100-00006 · Cited by 191
Wilens, T. E., McBurnett, K., Bukstein, O., McGough, J., Greenhill, L., Lerner, M., Stein, M. A., Conners, C. K., Duby, J., Newcorn, J., et al. (2006) · Archives of Pediatrics & Adolescent Medicine · doi:10.1001/archpedi.160.1.82 · Cited by 160
Self-citationLong-term atomoxetine treatment in adolescents with attention-deficit/hyperactivity disorder
Wilens, T. E., Newcorn, J. H., Kratochvil, C. J., Gao, H., Thomason, C. K., Rogers, A. K., Feldman, P. D., & Levine, L. R. (2006) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2006.01.052 · Cited by 102 · cited 5×
“The rate of irritability exceeds that typically observed with either ATMX or OROS MPH alone (Swanson et al. 2004; Wilens et al. 2006; Newcorn et al. 2008).”
InfluentialSelf-citationHepatic Events Associated with Atomoxetine Treatment for??Attention-Deficit??Hyperactivity Disorder
Bangs, M. E., Jin, L., Zhang, S., Desaiah, D., Allen, A. J., Read, H. A., Regev, A., & Wernicke, J. F. (2008) · Drug Safety · doi:10.2165/00002018-200831040-00008 · Cited by 68
Do Children and Adolescents With ADHD Respond Differently to Atomoxetine?
Wilens, T. E., Kratochvil, C., Newcorn, J. H., & Gao, H. (2006) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/01.chi.0000190352.90946.0b · Cited by 59 · cited 5×
“The rate of irritability exceeds that typically observed with either ATMX or OROS MPH alone (Swanson et al. 2004; Wilens et al. 2006; Newcorn et al. 2008).”
InfluentialSelf-citation
Cited by
Storebø, O. J., Pedersen, N., Ramstad, E., Kielsholm, M. L., Nielsen, S. S., Krogh, H. B., Moreira-Maia, C. R., Magnusson, F. L., Holmskov, M., Gerner, T., et al. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012069.pub2 · Cited by 321
Reed, V. A., Buitelaar, J. K., Anand, E., Day, K. A., Treuer, T., Upadhyaya, H. P., Coghill, D. R., Kryzhanovskaya, L. A., & Savill, N. C. (2016) · CNS Drugs · doi:10.1007/s40263-016-0349-0 · Cited by 113
“The manuscript was written using the seven predefined topics as headings, with all the papers selected during stages 2 and 3 [17–21, 25–89] referred to under the appropriate heading(s) in Sect.”
BackgroundMethodResultInfluentialTreuer, T., Gau, S. S.-F., Méndez, L., Montgomery, W., Monk, J. A., Altin, M., Wu, S., Lin, C. C. H., & Dueñas, H. J. (2013) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2012.0093 · Cited by 58
Wilens, T. E., Hammerness, P., Utzinger, L., Schillinger, M., Georgiopoulous, A., Doyle, R. L., Martelon, M., & Brodziak, K. (2009) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2008.0125 · Cited by 54
“Prior to specific recommendations, further examination of safety and tolerability issues on the combination (see Hammerness et al., 2009) and replication of efficacy data under controlled conditions with adequate comparators are necessary.”
Self-citationMetabolic, toxicological, and safety considerations for drugs used to treat ADHD
Duong, S., Chung, K., & Wigal, S. B. (2012) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2012.671295 · Cited by 42
Metadata
- Authors
- Hammerness, P., Georgiopoulos, A., Doyle, R. L., Utzinger, L., Schillinger, M., Martelon, M., Brodziak, K., Biederman, J., & Wilens, T. E.
- Venue
- Journal of Child and Adolescent Psychopharmacology
- Publisher
- SAGE Publications
- Published
- 2009-10
- Volume
- 19
- Issue
- 5
- Pages
- 493-499
- ISSN
- 1044-5463 (ISSN-L)
- 1557-8992
- OpenAlex
- W1968567868
- Cited by
- 43
- References
- 12
- FWCI
- 4.06
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.